A phase I/II trial (NCT05845671) of amivantamab (a bifunctional antibody anti-EGFR/MET) plus TKI is ongoing for 35 patients with NSCLC harboring ALK, ROS1, and RET fusions progressing on FDA-approved TKIs for their respective oncogene. Here, ROS1 is linked to non-small cell lung carcinoma.